Brigit Biofarmaka Teknologi Tbk. vs Summarecon Agung Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp254 (market cap 172.82B, 592.2K 24h volume), while Summarecon Agung Tbk. trades at Rp322 (market cap 5.05T, 29.26M 24h volume). The key difference: Summarecon Agung Tbk. is far larger — about 29.2× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Summarecon Agung Tbk. is more actively traded (29.26M versus 592.2K). Which is the better fit depends on your goals.
| OBAT | SMRA | |
|---|---|---|
Market Cap | 172.82B | 5.05T |
Volume | 592.2K | 29.26M |
Lot | 5.92K | 292.59K |
Turnover | 147.05M | 9.3B |
Average Price | 248.31 | 317.73 |
Value | 147.05M | 9.3B |
Indicative Equilibrium Price | 254 | 322 |
Indicative Equilibrium Volume | 10 | 3.02K |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →PT Summarecon Agung Tbk (the Company) was established within the framework of the Domestic Capital Investment Law based on notarial deed No. 308 dated November 26, 1975 of Ridwan Suselo, S.H. PT. Summarecon Agung Tbk is one of the nation`s leading township developers. Entering its twenty-forth year, the original 10-hectare landbank it started with has turned into a vibrant, 500 hectare township in North Jakarta where commercial vivacity peacefully coexists with its houses numbering in the tens of thousands.
Read more on SMRA →